Dangerous Drug: Vincristine Sulfate(LCR, VCR)
(vin kris’ teen)
vincristine sulfate liposome injection
Marqibo
PREGNANCY CATEGORY D
Drug Classes
Antineoplastic
Mitotic inhibitor
Therapeutic Actions
Mitotic inhibitor: Arrests mitotic division at the stage of metaphase by inhibiting microtubular formation; exact mechanism of action unknown.
Indications
Acute leukemia
Hodgkin lymphoma, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms tumor as part of combination therapy
Treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) who have relapsed after treatment with two or more regimens of antileukemia therapy (Marqibo)
Unlabeled uses: Kaposi sarcoma, breast cancer, bladder cancer, CNS tumors, multiple myeloma, chronic lymphocytic leukemia, idiopathic thrombocytopenic purpura
Contraindications and Cautions
Contraindicated with allergy to vincristine, leukopenia, acute infection, pregnancy, lactation, demyelinating form of Charcot-Marie-Tooth syndrome.
Use cautiously with neuromuscular disease, diabetes insipidus, hepatic impairment.
Available Forms
Injection—1 mg/mL; liposomal injection—5 mg/31 mL
Dosages
Adults
1.4 mg/m2 IV at weekly intervals.
Philadelphia chromosome–negative ALL: 2.25 mg/m2 IV over 1 hr every 7 days (Marqibo).
Pediatric patients
1–2 mg/m2 IV weekly. Maximum dose, 2 mg/dose.
Weight less than 10 kg or body surface area less than 1 m2: 0.05 mg/kg IV once per wk.
Weight more than 10 kg: 1–2 mg/m2 IV once per wk.
Geriatric patients or patients with hepatic impairment
For serum bilirubin exceeding 3 mg/dL, reduce dosage by 50%.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
